Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases

BMC Gastroenterology

Timothy Cushway²  Garth Virgin²  Suki Chainey¹  Simon Straub³  Martin W Laass³ 

[1] Statistics Department, Vifor Pharma Ltd, Flughofstrasse 61, Glattbrugg CH-8152, Switzerland;Medical Department, Vifor Pharma Ltd, Flughofstrasse 61, Glattbrugg CH-8152, Switzerland;Department of Pediatrics, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Fetscherstraβe 74, Dresden 01307, Germany

关键词: Anemia;    Iron deficiency;    Ferric carboxymaltose;    Intravenous iron;    IBD;    Pediatric;   

Others  :  1121777
DOI  :  10.1186/1471-230X-14-184

 received in 2014-03-30, accepted in 2014-10-09,  发布年份 2014

【 摘 要 】

Background

The treatment of iron deficiency anemia in children with inflammatory bowel disease is a particular challenge and often insufficient. Absorption of orally given iron may be impaired by intestinal inflammation and treatment with oral iron may aggravate intestinal inflammation. This retrospective study is the first to describe the use of intravenous ferric carboxymaltose (FCM) in the pediatric setting.

Methods

All subjects who had received at least one dose of FCM intravenously in the observation period were included in this analysis with data collected for up to 3 months post last FCM dose.

Results

In total, 72 children between 0 and 18 years with underlying gastrointestinal disorders had been treated for concomitant iron deficiency anemia. The majority of patients had Crohn’s disease (40.3%) or ulcerative colitis (30.5%). The total number of FCM administrations was 147, the mean number per patient was 2.0 and the mean cumulative dose 821 mg iron (median single dose: 500 mg; max. 1000 mg). Post administration of FCM, correction of iron deficiency anemia was observed with improved mean hemoglobin levels from 9.5 g/dL at baseline to 11.9 g/dL within 5–12 weeks. Decreases in white cell count, platelets and C-reactive protein were observed post FCM, potentially suggesting reduced inflammation with iron repletion. Three subjects reported mild adverse drug reactions related to FCM; two of these were considered to be potentially related to long duration of administration and to high volume of saline solution for dilution. As such, the method of administration was amended to have a maximum infusion time of 60 minutes and dilution with less than or equal to 100 mL saline solution.

Conclusions

Overall FCM was well tolerated in this pediatric population and appeared to be effective in correcting iron deficiency anemia. We cannot exclude that the correction of iron deficiency anaemia is in some part due to the treatment of the underlying disease and not related to the iron supplementation only.

【 授权许可】

   
2014 Laass et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Wiskin AE, Fleming BJ, Wootton SA, Beattie RM: Anaemia and iron deficiency in children with inflammatory bowel disease. J Crohns Colitis 2012, 6:687-691.
• [2]Goodhand JR, Kamperidis N, Rao A, Laskaratos F, McDermott A, Wahed M, Naik S, Croft NM, Lindsay JO, Sanderson IR, Rampton DS: Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:513-519.
• [3]Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, Wahbeh GT, Sena LM, Faubion WA: Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012, 55:93-108.
• [4]Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, Gomollon F, Hjortswang H, Koutroubakis I, Kulnigg S, Oldenburg B, Rampton D, Schroeder O, Stein J, Travis S, Van Assche G: Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007, 13:1545-1553.
• [5]Lozoff B, Beard J, Connor J, Barbara F, Georgieff M, Schallert T: Long-lasting neural and behavioral effects of iron deficiency in infancy. Nutr Rev 2006, 64:S34-S43.
• [6]Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP: Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther 2001, 15:1989-1999.
• [7]Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J: Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005, 100:2503-2509.
• [8]Lee TW, Kolber MR, Fedorak RN, van Zanten SV: Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis 2012, 6:267-275.
• [9]Thayu M, Mamula P: Treatment of iron deficiency anemia in pediatric inflammatory bowel disease. Curr Treat Options Gastroenterol 2005, 8:411-417.
• [10]Kent AJ, Blackwell VJ, Travis SP: What is the optimal treatment for anemia in inflammatory bowel disease? Curr Drug Deliv 2012, 9:356-366.
• [11]Beigel F, Löhr B, Laubender RP, Tillack C, Schnitzler F, Breiteneicher S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S: Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Digestion 2012, 85:47-54.
• [12]Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D’Haens G, Gasche C: A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008, 103:1182-1192.
• [13]Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group: FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011, 141:846-853.
• [14]Periodic Safety Update Report for Ferinject: Vifor Pharma (PSUR PVZ-VIT45/E09) dated 16-Aug-2013. Submitted to the MHRA, UK being the Reference Member State for the registration of Ferinject
• [15]Ganzoni AM: Intravenous iron dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970, 100:301-303.
• [16]Lyseng-Williamson and Keating: Ferric Carboxymaltose - A Review of its Use in Iron-Deficiency Anaemia. Drugs 2009, 69:739-756.
• [17]Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C, FERGI Study Group: Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013, 11:269-277.
• [18]Pels LP, Van de Vijver E, Waalkens HJ, Uitentuis J, Gonera-de Jong G, van Overbeek LA, Norbruis OF, Rings EH, van Rheenen PF: Slow hematological recovery in children with IBD-associated anemia in cases of “expectant management”. J Pediatr Gastroenterol Nutr 2010, 51:708-713.
• [19]Kulnigg-Dabsch S, Evstatiev R, Dejaco C, Gasche C: Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS One 2012, 7:e34520.